NCT01097460

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

MM-111-02-12-02: A Phase 1 Study of MM-111 in Combination With Herceptin in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Breast Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Merrimack Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label Phase 1 trial of MM-111 in combination with Herceptin.

Detailed description

Phase 1: Safety and tolerability of the MM-111 + Herceptin combination will be evaluated and the recommended Phase 2 dose will be determined.

Conditions

• Breast Neoplasms

Interventions

Type	Name	Description
DRUG	MM-111 + Herceptin	For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV

Timeline

• Start date: 2010-04-01
• Primary completion: 2013-07-01
• Completion: 2013-07-01
• First posted: 2010-04-01
• Last updated: 2015-01-07
• Results posted: 2014-12-04

Locations

3 sites across 1 country: United States